Allergy Immunotherapy Market Research Report By Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy, Oral Immunotherapy), By Product (Allergen Extracts, Conventional Immunotherapy, Biologics), By Indication (Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, Food Allergies), By Patient Type (Pediatric, Adult, Geriatric) andBy Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa)- Forecast to 2035

Allergy Immunotherapy Market Overview

As per MRFR analysis, the Allergy Immunotherapy Market Size was estimated at 5.32 (USD Billion) in 2023. The Allergy Immunotherapy Market Industry is expected to grow from 5.71(USD Billion) in 2024 to 12.5 (USD Billion) by 2035.

The Allergy Immunotherapy Market CAGR (growth rate) is expected to be around 7.38% during the forecast period (2025 - 2035).

Key Allergy Immunotherapy Market Trends Highlighted

The Global Allergy Immunotherapy Market is undergoing a transition to personalized treatment approaches, which is being driven by a growing comprehension of the genetic and environmental factors that influence allergic diseases. This trend is additionally reinforced by the development of diagnostic tools that enable the development of immunotherapy solutions that are customized to the unique profiles of individual patients.

Additionally, the increasing prevalence of allergies across a variety of demographics, as emphasized by global health organizations, is driving the demand for effective treatment options, resulting in immunotherapy being the preferred preference among healthcare providers.

Regulatory bodies are highlighting the significance of innovative remedies to address the increasing public health concerns associated with allergies, which is resulting in the expansion of market opportunities.

Some areas in which companies can investigate new product offerings include the development of sublingual immunotherapy and more effective delivery methods. Furthermore, the increased global awareness of allergies has resulted in a growing number of partnerships between pharmaceutical companies and healthcare providers, which has resulted in improved patient care and treatment adherence.

Recent trends suggest a significant increase in the utilization of combination therapies, which involve the use of immunotherapy in conjunction with conventional medications to improve the overall efficacy of allergy management. This method not only enhances treatment outcomes but also offers a more comprehensive management strategy for patients.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Allergy Immunotherapy Market Drivers

Rising Incidence of Allergies Globally

The Global Allergy Immunotherapy Market Industry is significantly driven by the rising incidence of allergic disorders across the globe.

According to the World Health Organization (WHO), allergic diseases such as hay fever, asthma, and allergic rhinitis have been increasing, with estimates suggesting that about 30% of the global population suffers from one or more allergic conditions. This rise in allergy prevalence demands effective treatment options, such as immunotherapy.

Established organizations like the American Academy of Allergy, Asthma, and Immunology (AAAAI) emphasize the importance of immunotherapy in managing allergies, showing a correlation with an increasing number of patients seeking these therapies.

Furthermore, a report from the European Academy of Allergy and Clinical Immunology indicates that the prevalence of allergic diseases is expected to rise by 50% by 2030 in various regions, including Europe and North America, solidifying the urgent need for innovative solutions in the Global Allergy Immunotherapy Market Industry.

Advancements in Immunotherapy Techniques

The Global Allergy Immunotherapy Market Industry is benefitting from the rapid advancements in immunotherapy techniques, including sublingual immunotherapy and monoclonal antibodies. Recent studies have demonstrated that these advanced therapies can offer faster relief and improved safety profiles compared to traditional methods.

The International Pharmaceutical Federation has reported an increase in innovative treatment modalities that have shown a 60% effectiveness rate in managing allergic rhinitis symptoms, thereby boosting patient compliance.

Companies like Novartis and Pfizer are heavily investing in Research and Development (R) to create next-generation allergy treatments, positioning themselves prominently in the Global Allergy Immunotherapy Market Industry.

Increased Awareness and Diagnosis of Allergies

Awareness of allergies and their potential impact on quality of life is increasing worldwide, propelling growth in the Global Allergy Immunotherapy Market Industry. Health campaigns led by organizations such as the Allergic Rhinitis and its Impact on Asthma (ARIA) initiative aim to highlight the importance of allergy diagnosis and treatment options.

As a result, the worldwide diagnosis of allergic conditions has witnessed a significant increase of 20% over the past decade.

The enhanced diagnostics and public awareness are motivating more patients to seek immunotherapy solutions, as evident from the rising consult rates in allergy clinics. This trend is being supported by national health policies promoting better allergy management strategies.

Allergy Immunotherapy Market Segment Insights

Allergy Immunotherapy Market Type Insights

The Global Allergy Immunotherapy Market, particularly focusing on the Type segment, showcases a robust landscape with significant revenue growth projections, expected to reach 5.71 USD Billion by 2024 and continue to evolve to 12.5 USD Billion by 2035.

This market consists of various types of immunotherapy, prominently including Subcutaneous Immunotherapy, Sublingual Immunotherapy, and Oral Immunotherapy. In terms of segmentation within this market, Subcutaneous Immunotherapy holds a notable position with a valuation of 2.25 USD Billion in 2024 and an increase to 4.8 USD Billion by 2035, representing a majority holding in the sector due to its established efficacy and widespread acceptance among healthcare providers.

This method involves administering allergens via injections and allows for controlled dosage delivery, which can lead to long-term relief from allergic reactions. Sublingual Immunotherapy, valued at 2.0 USD Billion in 2024 and expected to rise to 5.0 USD Billion by 2035, is also gaining traction due to its non-invasive administration method, requiring patients to place allergen tablets under their tongues, making it a popular choice for those reluctant to receive injections.

This type of oral administration approach contributes to the market's accessibility, particularly appealing to patients looking for a convenient alternative.Lastly, Oral Immunotherapy, starting at a valuation of 1.46 USD Billion in 2024 and anticipated to increase to 2.7 USD Billion by 2035, addresses specific food allergies and represents a significant innovation in allergen management.

The growth in oral options aligns with a general trend toward more patient-centric treatment approaches and reflects increased research and development efforts targeting food-allergic sensitivities. The Global Allergy Immunotherapy Market data and statistics underline the increasing prevalence of allergy cases worldwide, driving demand for diverse treatment methods.

These segments not only highlight the varying preferences among patients but also underscore the robust potential for growth fueled by advancements in clinical research and raising awareness about allergy management alongside preventative healthcare trends.

This adaptability and responsiveness to patient needs play a crucial role in shaping the market's future dynamics, providing compelling opportunities for growth within the Global Allergy Immunotherapy Market industry.

Overall, the Type segment exhibits a diverse yet interconnected array wherein each subcategory embraces opportunities shaped by evolving consumer behavior and regulatory advancements within the global healthcare landscape.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Allergy Immunotherapy Market Product Insights

The Global Allergy Immunotherapy Market is projected to be valued significantly at 5.71 USD Billion in 2024, with substantial growth anticipated by 2035. This growth is driven by the increasing incidence of allergic conditions and rising awareness regarding immunotherapy among patients and healthcare professionals.

The market segmentation includes Allergen Extracts, Conventional Immunotherapy, and Biologics, with each playing a crucial role. Allergen Extracts often represent a major portion of the market due to their effectiveness in providing targeted treatment for specific allergies.

Conventional Immunotherapy remains important for its established methods and long-term benefits, which are crucial for managing allergy symptoms over time. Biologics, an emerging area, is gaining traction due to advancements in biotechnology, offering innovative treatment options that cater to complex allergic reactions.

The Global Allergy Immunotherapy Market industry continues to evolve, presenting opportunities for expansion, driven by technological innovations and a growing patient base seeking effective allergy management solutions.

Current Global market data highlights the significant demand for these products, as they contribute substantially to improving patient quality of life and reducing the burden of allergy-related symptoms.

Allergy Immunotherapy Market Indication Insights

The Global Allergy Immunotherapy Market, with an expected valuation of 5.71 billion USD in 2024, showcases a robust landscape driven by various indications, including Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, and Food Allergies. Allergic Rhinitis and Allergic Asthma represent significant portions of the market due to their prevalence and impact on quality of life, affecting millions globally.

The increasing awareness and understanding of these conditions have led to a surge in demand for immunotherapy treatments tailored to individual patient needs.

Atopic Dermatitis and Food Allergies are also gaining traction, with a notable increase in their associated market statistics and growth potential. Factors such as rising healthcare spending and advancements in treatment methodologies fuel market growth. However, challenges like regulatory hurdles and the need for extensive Research and Development to tailor therapies to diverse patient demographics remain.

Continued investment in innovative treatments presents ample opportunities within these indications, indicating a dynamic market trajectory for the Global Allergy Immunotherapy Market. The trends point towards personalized medicine as an emerging focal point in improving patient outcomes.

Allergy Immunotherapy Market Patient Type Insights

The Global Allergy Immunotherapy Market, projected to reach a value of 5.71 billion USD by 2024, showcases a notable segmentation based on Patient Type, primarily encompassing Pediatric, Adult, and Geriatric categories.

Each of these sections plays a crucial role in market growth, given their unique needs and responses to allergy treatments. Pediatric patients often require specialized formulations and dosing, as young immune systems react differently to allergens.

The Adult sector dominates the market, driven by rising allergy prevalence and awareness about immunotherapy options.Geriatric patients, while a smaller group, face increasing allergies due to age-related immune changes, making them a significant demographic for tailored therapies.

This segmentation underlines the market's adaptability, catering to distinct patient requirements and fostering substantial opportunities for innovation, with market growth propelled by increased healthcare investments and a growing understanding of allergy immunotherapy effectiveness across all ages.

The Global Allergy Immunotherapy Market data reflects these trends, establishing a robust framework for industry advancements and strategic initiatives.

Allergy Immunotherapy Market Regional Insights

The Global Allergy Immunotherapy Market reveals significant regional segmentation, with North America leading the market, valued at 2.3 USD Billion in 2024 and expected to rise to 5.1 USD Billion by 2035, showcasing a majority holding in the market dynamics.

Europe follows, with a valuation of 1.6 USD Billion in 2024, projected to reach 3.4 USD Billion in 2035, driven by rising allergy incidences and strong healthcare infrastructure. The APAC region, valued at 1.1 USD Billion in 2024 and anticipated to grow to 2.5 USD Billion by 2035, is gaining traction due to an increasing population prone to allergies and improving access to immunotherapy.

South America, with a market valuation of 0.5 USD Billion in 2024, is expected to see growth to 1.0 USD Billion in 2035, showing the potential for expansion as awareness and healthcare services improve. The MEA region, though smaller, valued at 0.25 USD Billion in 2024, has the potential to grow to 0.6 USD Billion by 2035, fueled by increasing healthcare spending and awareness of allergy treatments.

Overall, the Global Allergy Immunotherapy Market statistics reflect varied growth prospects across these regions, with each demonstrating unique opportunities driven by healthcare advancements and increasing patient awareness.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Allergy Immunotherapy Market Key Players and Competitive Insights

The Global Allergy Immunotherapy Market has undergone significant transformations in recent years, marked by advancements in technology and an increasing understanding of immunological mechanisms that drive allergic responses.

This market is characterized by a diverse set of players vying for dominance, each bringing unique therapeutic solutions aimed at alleviating allergic conditions such as allergic rhinitis, asthma, and food allergies.

The competition is sparked by a growing patient population and a shift towards personalized medicine approaches, along with a stronger emphasis on novel treatment methodologies, including sublingual and epicutaneous immunotherapy routes.

Companies are focusing on robust clinical trials and findings to establish the effectiveness and safety of their products, which helps shape the competitive landscape of this vibrant market.

HollisterStier, a prominent player in the Global Allergy Immunotherapy Market, is recognized for its strong foothold in the provision of diagnostic and therapeutic solutions related to allergies.

The company boasts a comprehensive portfolio that addresses a variety of allergic conditions, contributing to its market presence.

HollisterStier has built a reputation for its high-quality allergen extracts and immunotherapy products, which are influential in both the treatment and understanding of allergies.

The strengths of HollisterStier lie in its commitment to research and development, allowing for innovative product offerings and the ability to respond effectively to shifting market dynamics.

Their established distribution networks facilitate wide reach, enhancing patient access to essential immunotherapy treatments.

Meanwhile, DBV Technologies has emerged as a notable contender in the Global Allergy Immunotherapy Market with a focus on developing innovative therapies for food allergies, particularly their flagship product, which utilizes a unique epicutaneous immunotherapy approach.

This differentiation positions DBV Technologies favorably in a competitive landscape where conventional treatments are prevalent.

Their strategic focus on food allergen therapies targets a significant unmet need in the global market. As an innovative company, DBV Technologies has strengthened its presence through numerous collaborations and partnerships aimed at expediting product development, which complements its strong intellectual property portfolio.

Recent mergers and acquisitions have further bolstered its capabilities and market reach, emphasizing its commitment to advancing treatments that can significantly improve the quality of life for those suffering from severe food allergies on a global scale.

Key Companies in the Allergy Immunotherapy Market Include

• HollisterStier


• DBV Technologies


• Aimmune Therapeutics


• ALK Abello


• Boehringer Ingelheim


• UCB


• Stallergenes Greer


• Novartis


• Mylan


• Allergopharma


• R HSBC


• Bayer


• Merck


• GlaxoSmithKline


• Sanofi

Allergy Immunotherapy Market Industry Developments

Recent developments in the Global Allergy Immunotherapy Market indicate significant activity among key players such as HollisterStier, DBV Technologies, and Aimmune Therapeutics.

Notably, ALK Abello has expanded its product offerings, focusing on personalized treatments that cater to specific allergens. At the same time, Boehringer Ingelheim and UCB continue to enhance their Research and Development efforts in immunotherapeutics.

Mylan and Allergopharma are engaging in strategic partnerships to expedite the launch of new therapies. In September 2023, Stallergenes Greer announced an acquisition of a small biotech firm to bolster its portfolio in sublingual immunotherapy, reflecting a trend of consolidation among established companies.

Additionally, Novartis and Merck announced collaborative agreements enhancing their respective immunotherapy product lines, a move emphasizing adaptive innovation in the market. The market valuation has been positively impacted, showing steady growth attributed to the increasing prevalence of allergic conditions and rising demand for effective treatments.

The Global Allergy Immunotherapy Market is anticipated to evolve significantly, bolstered by these strategic initiatives and a heightened focus on personalized medicine over the past few years, including major advancements noted in early 2022.

Allergy Immunotherapy Market Segmentation Insights

Allergy Immunotherapy Market Type Outlook

• Subcutaneous Immunotherapy


• Sublingual Immunotherapy


• Oral Immunotherapy

Allergy Immunotherapy Market Product Outlook

• Allergen Extracts


• Conventional Immunotherapy


• Biologics

Allergy Immunotherapy Market Indication Outlook

• Allergic Rhinitis


• Allergic Asthma


• Atopic Dermatitis


• Food Allergies

Allergy Immunotherapy Market Patient Type Outlook

• Pediatric


• Adult


• Geriatric

Allergy Immunotherapy Market Regional Outlook

• North America


• Europe


• South America


• Asia Pacific


• Middle East and Africa

Report Attribute/Metric Source:	Details
MARKET SIZE 2023	5.32(USD Billion)
MARKET SIZE 2024	5.71(USD Billion)
MARKET SIZE 2035	12.5(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	7.38% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Billion
KEY COMPANIES PROFILED	HollisterStier, DBV Technologies, Aimmune Therapeutics, ALK Abello, Boehringer Ingelheim, UCB, Stallergenes Greer, Novartis, Mylan, Allergopharma, R HSBC, Bayer, Merck, GlaxoSmithKline, Sanofi
SEGMENTS COVERED	Type, Product, Indication, Patient Type, Regional
KEY MARKET OPPORTUNITIES	Expanding patient awareness programs, Innovative treatment delivery methods, Growing demand for personalized medicine, Increased R&D investment, Strategic partnerships and collaborations
KEY MARKET DYNAMICS	Increasing allergic conditions prevalence, Technological advancements in therapies, Rising awareness of immunotherapy, Growing investment in R&D, Favorable regulatory environment
COUNTRIES COVERED	North America, Europe, APAC, South America, MEA